Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Downgrades Coupa Software to Market Perform

William Blair analyst Robert Napoli downgrades Coupa Software (NASDAQ:COUP) from Outperform to Market Perform.

byBenzinga Newsdesk

December 12, 2022

1 minute read

William Blair analyst Robert Napoli downgrades Coupa Software (NASDAQ:COUP) from Outperform to Market Perform.

Watching CenterPoint Energy Shares; Seeing Reports Of Fire At Co’s Substation In Houston, Texas

By Benzinga Newsdesk

Today, 12:50 PM

https://twitter.com/PMBreakingNews/status/1413547268653846537?s=20

CNP

News

‘Tesla Ramps Up Hiring For Megafactory, Aiming To Produce 40 GWh Per Year’ – Electrek

By Benzinga Newsdesk

Today, 12:50 PM

https://electrek.co/2022/09/08/tesla-ramps-up-hiring-megafactory/ Tesla is ramping up hiring for its Megafactory in California, where it aims to produce 40 GWh of Megapacks per year. Last

TSLA

CommVault Systems Q3 Adj EPS $0.62 Misses $0.65 Estimate, Sales $195.10M Miss $197.41M Estimate

By Benzinga Newsdesk

Today, 12:50 PM

CommVault Systems (NASDAQ:CVLT) reported adjusted quarterly earnings of $0.62 per share which missed the analyst consensus estimate of $0.65 by 4.62 percent. This is a 7.46 percent decrease over earnings of $0.67 per

CVLT

Alexion’s Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder

By Vandana Singh

Today, 12:50 PM

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis…

ALXN

William Blair Downgrades Coupa Software to Market Perform

Related Posts

Watching CenterPoint Energy Shares; Seeing Reports Of Fire At Co’s Substation In Houston, Texas

‘Tesla Ramps Up Hiring For Megafactory, Aiming To Produce 40 GWh Per Year’ – Electrek

CommVault Systems Q3 Adj EPS $0.62 Misses $0.65 Estimate, Sales $195.10M Miss $197.41M Estimate

Alexion’s Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder